Human Papillomavirus (HPV)-vaccine produced in bacterial cells
Cervical cancer is one of the most common cancers in women worldwide and the incidence correlates with HPV (human Papillomavirus) infection. The two commercially available vaccines against HPV only protect against new infections (prophylactic vaccination), whereas existing infections are not cleared. The current technology provides a vaccine with the capability to function both as a prophylactic and a therapeutic vaccine. Moreover, it can be produced in bacterial cells, which makes production very cost-effective.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…
